Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Clene Inc.NASDAQ: CLNN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $329K fell 77.8% year over year, behind the -17.9% change in trailing-twelve-month research & development. Sequentially, it fell 94.0% from the prior quarter. Over 3 fiscal years it compounded at -24.0% a year.
Context
- Research & development amounted to 7005.5% of revenue in FY2025, up 1140.6 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -77.8% toward the trailing-twelve-month pace of -17.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.01M USD
- Year-over-year change
- -30.1%
- 4-year CAGR
- -16.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.01M | -30.1% |
| FY2024 | 2024-12-31 | 20.06M | -24.7% |
| FY2023 | 2023-12-31 | 26.66M | -16.5% |
| FY2022 | 2022-12-31 | 31.92M | +12.3% |
| FY2021 | 2021-12-31 | 28.42M | — |
Research & Development vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's LTM Mar 2026 research & development of $12.86M is the 10th highest of the 11 companies compared; the peer median is $58.42M.
- Its year-over-year change of -17.9% is the 6th highest of 11, against a peer median of -14.4%.
- Research & development amounts to 9596.3% of revenue for CLNN, versus a peer median of 3629.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M | +115.1% | +40.7% | — |
| LTM Mar 2026 | $79.04M | -54.8% | +4.0% | — | |
| FY2025 | $37.8M | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $36.3M | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M | +46.4% | +65.0% | — | |
| LTM Mar 2026 | $30.07M | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | $12.86M | -17.9% | -24.0% | 9596.3% | |
| LTM Mar 2026 | $5.77M | -21.5% | -38.7% | — | |
| Peer median (excluding CLNN) | $58.42M | -14.4% | -5.5% | 3629.9% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 723K | 473K | 654K | 342K | 200K |
| Cost of Revenue | 289K | 26K | 121K | 70K | 43K |
| Gross Profit | 434K | 447K | 533K | 272K | 157K |
| Gross Margin | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| Research & Development | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
| Selling, General & Admin | 18.81M | 16.16M | 14.42M | 13.31M | 9.23M |
| Operating Expenses | 50.41M | 48.86M | 41.07M | 33.37M | 23.24M |
| Depreciation & Amortization | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| EBITDA | (8.34M) | (25.6M) | (43.24M) | (33.69M) | (22M) |
| EBITDA Margin | -1153.9% | -5412.9% | -6611.8% | -9851.2% | -10998.0% |
| Operating Income | (49.98M) | (48.41M) | (40.54M) | (33.09M) | (23.08M) |
| Operating Margin | -6912.6% | -10234.5% | -6198.8% | -9676.3% | -11541.5% |
| Interest Income | 0 | 0 | 1.39M | 865K | 223K |
| Interest Expense | 870K | 3.3M | 4.56M | 4.06M | 2.68M |
| Other Income / Expenses | 39.81M | 18.49M | (8.96M) | (6.31M) | (3.09M) |
| Income Before Tax | (10.17M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Pre-Tax Margin | -1406.4% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| Income Tax Expense | (428K) | 0 | 0 | 0 | 0 |
| Net Income | (9.74M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Net Margin | -1347.2% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| EPS (Basic) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| EPS (Diluted) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| Weighted Avg Shares | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
| Weighted Avg Shares (Diluted) | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.